Valion Bio Inc (VBIO) Stock

NASDAQ: VBIOHealthcare company in the biotechnology industry, based in San Antonio, TX.

Valion Bio stock price chart

VBIO interactive chart →

VBIO stock quote & key statistics

Valion Bio earnings per share

Income →
Earnings per share

Valion Bio revenue & net income

Income →
RevenueNet income

Valion Bio annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$382,000-$8.9M—
FY2024$0-$5.7M-$727.55
FY2023$1.2M-$8.2M-$5469.38
FY2022$1.8M-$10.1M-$11193.04
FY2021$1.3M-$8.5M-$16290.91

Fiscal year ending December 31. Source: company filings via EODHD.

About Valion Bio Inc

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services.

The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Valion Bio stock FAQ

What is the Valion Bio stock ticker symbol?

Valion Bio Inc trades on the NASDAQ under the ticker symbol VBIO.

What sector and industry is Valion Bio in?

Valion Bio Inc is classified in the Healthcare sector, Biotechnology industry.

How many employees does Valion Bio have?

Valion Bio Inc has about 52 full-time employees.

What were Valion Bio's revenue and earnings last fiscal year?

Valion Bio reported revenue of $382,000 and net income of -$8.9M in fiscal 2025.

When did Valion Bio go public?

Valion Bio stock began trading on November 11, 2021.

Biotechnology stocks

All Healthcare stocks →